Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Shaker R. Dakhil"'
Autor:
Michelle C. Janelsins, Jodi Geer, Charles Kamen, Allison Magnuson, Patrick M. Reagan, Mostafa R. Mohamed, Supriya G. Mohile, Luke J. Peppone, Charles E. Heckler, Marianne Melnik, Elizabeth Belcher, Gary R. Morrow, Tim A. Ahles, Shaker R. Dakhil, Lori M. Minasian
Publikováno v:
J Natl Cancer Inst
Background Cancer-related cognitive decline (CRCD) is an important clinical problem, but limited research exists on assessment of cognitive function in patients with lymphoma. Methods The overall objective of this nationwide, prospective, observation
Autor:
Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, Michael G Haddock, Shaker R Dakhil, Robert J Behrens, Steven R Alberts
Publikováno v:
The oncologist. 27(7)
Background This North Central Cancer Treatment Group (NCCTG) N064A (Alliance) phase II trial evaluated upfront chemoradiotherapy incorporating the EGFR inhibitor panitumumab, followed by gemcitabine and panitumumab for unresectable, non-metastatic pa
Autor:
Wen Hong Lin, Carlos H. Barrios, Martin Reck, Ramaswamy Govindan, Neal Ready, Dimple Pandya, Hye Ryun Kim, Taofeek K. Owonikoko, Alejandro Navarro, Keunchil Park, Laurent Greillier, Ivor John Percent, Vanesa Gutierrez, Miten Patel, Jong Seok Lee, Parul Doshi, Michael Schenker, Solange Peters, Shaker R. Dakhil, Jerónimo Rodríguez-Cid, Daniel Morgensztern, Christine Baudelet, Sofia Baka, Jonathan F. Baden, Giovanni Selvaggi
Publikováno v:
Journal of clinical oncology, vol. 39, no. 12, pp. 1349-1359
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (12), pp.1349-1359. ⟨10.1200/JCO.20.02212⟩
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (12), pp.1349-1359. ⟨10.1200/JCO.20.02212⟩
PURPOSE In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::362dcb13447f71920cccc0d1cd6b0b79
https://serval.unil.ch/resource/serval:BIB_78F0D04B7BA3.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_78F0D04B7BA3.P001/REF.pdf
Autor:
Daniel J. George, Joel Picus, Olwen Hahn, Darren R. Feldman, Shaker R. Dakhil, Meghara K. Walsh, Susan Halabi, Colin Hessel, Michael J. Morris, Toni K. Choueiri, Christian Scheffold, M. Dror Michaelson, Eric J. Small, Milan Mangeshkar
Publikováno v:
The Oncologist
The phase II CABOSUN trial compared cabozantinib with sunitinib as initial treatment in patients with advanced renal cell carcinoma of intermediate or poor risk. This article presents subgroup analyses by baseline patient characteristics.
Caboza
Caboza
Autor:
W. Ken Zhen, Yolanda I. Garces, James L. Leenstra, Shaker R. Dakhil, Terence T. Sio, Apar Kishor Ganti, Daniel J. Ma, Jean-Claude M. Rwigema, Levi Pederson, Sonja J. van der Veen, Steven E. Schild, James D. Bearden, Pamela J. Atherton, Robert C. Miller, Robert W. Mutter
Publikováno v:
International Journal of Radiation Oncology Biology Physics, 103(3), 686-696. ELSEVIER SCIENCE INC
Purpose: Chemoradiation (CRT) is an integral treatment modality for patients with locally advanced lung cancer. It has been hypothesized that current use of an angiotensin-converting enzyme inhibitor during CRT may be protective for treatment-related
Autor:
Charles L. Loprinzi, Teri Britt Pipe, Timothy J. Hobday, Rui Qin, Debra L. Barton, Kelli Fee-Schroeder, Shaker R. Dakhil, Daniel Satele, Pamela J. Atherton
Publikováno v:
Support Care Cancer
Sleep disturbance is a prevalent problem for cancer survivors and effective behavioral treatments are not widely used for this population. This study evaluated home-based sleep interventions based on cognitive behavioral therapy for insomnia (CBT-I).
Autor:
Jeffrey A. Sosman, Gary I. Cohen, Lawrence E. Flaherty, Robert M. Conry, Alberto S. Pappo, Richard F. Kefford, Joanna M. Brell, Michael Smylie, Douglas S. Reintgen, John M. Kirkwood, William E. Carson, Sandra J. Lee, Sanjiv S. Agarwala, Shaker R. Dakhil, Terry L. Evans, Mark R. Albertini, Uma N. M. Rao, Wai-Ki Yip, Michael B. Atkins, Vernon K. Sondak, Ahmad A. Tarhini
Publikováno v:
Journal of Clinical Oncology. 35:885-892
Purpose To test the efficacy of 4 weeks of intravenous (IV) induction with high-dose interferon (IFN) as part of the Eastern Cooperative Oncology Group regimen compared with observation (OBS) in patients with surgically resected intermediate-risk mel
Autor:
Darren R. Feldman, Toni K. Choueiri, Joel Picus, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Shaker R. Dakhil, Daniel J. George, Meghara K. Walsh, Thomas Olencki, Eric J. Small, Susan Halabi, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 35:591-597
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cab
Autor:
Stuart L. Goldberg, Jerald P. Radich, Martha Wadleigh, Bret Helton, Ilva Dautaj, Carole Paley, Jesus G. Berdeja, Philip Kuriakose, Jorge E. Cortes, Shaker R. Dakhil, Michael Heinrich, Michael J. Mauro, David A. Rizzieri
Publikováno v:
Leukemialymphoma. 60(10)
ENESTnext (NCT01227577) was a single-arm, multicenter trial evaluating the rate of deep molecular response by 2 years in patients with newly diagnosed (within 6 months) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib 300 mg
Autor:
N. Lynn Henry, Robert A. Bagramian, Mark M. Schubert, Amy K. Darke, Shaker R. Dakhil, Danika L. Lew, Catherine Van Poznak, James L. Wade, Dawn L. Hershman, Justin D. Floyd, Carol M. Moinpour, Michael J. Fisch, Joseph M. Unger, Lisa Hansen, Julie R. Gralow
Publikováno v:
JAMA Oncol
Importance Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence is unknown. Objective To define the cumulative incidence of ONJ at 3 years in p